BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy, Temple Terrace, FL
Is BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy in Temple Terrace, FL, first registered Jun 4, 2019 and most recently registered Feb 5, 2026. FDA lists its last inspection as Mar 12, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “FMD-145 Letter Issued 9/18/2023”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Temple Terrace, FL
- Initial registration
- Jun 4, 2019
- Most recent registration
- Feb 5, 2026
- Last inspection
- Mar 12, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- FMD-145 Letter Issued 9/18/2023
- Intends to compound sterile drugs from bulk substances
- No
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Baycare Integrated Service Center, LLC dba BayCare Central Pharmacy, Temple Terrace, FL, a 503B facility, with 6 listed actions, including 3 Form 483s and 1 untitled letter (2019 to 2026).
| Document | |||
|---|---|---|---|
| Mar 12, 2026 | Form 483 | 483 Issued 3/12/2026 | fda.gov |
| Sep 15, 2023 | FMD-145 letter | FMD-145 Letter Issued 09/15/2023 | Not linked by FDA |
| Jun 2, 2023 | Form 483 | 483 Issued 06/02/2023 | FDA copy (archived) |
| Apr 4, 2022 | FMD-145 letter | FMD-145 Letter Issued 04/04/2022 | Not linked by FDA |
| Sep 13, 2021 | Untitled letter | Untitled Letter Issued 09/13/2021 | FDA copy (archived) |
| Dec 10, 2019 | Form 483 | 483 Issued 12/10/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists BayCare Integrated Service Center LLC, Temple Terrace, FL (FEI number 3013023419), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 2, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013023419 | 1206889 |
| Dec 10, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013023419 | 1112266 |
Form 483s FDA has published for this site
- Mar 12, 2026: Form 483 to BayCare Integrated Service Center LLC, published Apr 22, 2026. fda.gov
- Jun 2, 2023: Form 483 to BayCare Integrated Service Center LLC, published Jul 28, 2023. fda.gov
- Dec 10, 2019: Form 483 to BayCare Integrated Service Center LLC, published Oct 5, 2021. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending Dec 10, 2019 to Mar 12, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 17, 2026 to Mar 12, 2026: 9 observations
- Firm on the cover
- BayCare Integrated Service Center LLC, 7802 E Telecom Pkwy, Temple Terrace, FL 33637-0928
- FEI number
- 3013023419
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. Your firm does not routinely conduct dynamic viable air monitoring within the critical ISO 5 classified filling zone of the <Redacted B4> machine cell area throughout filling operations as required by SOP P-204.7 "Quality Management J Program for: Environmental and Personnel Sampling". The procedures requires that for <Redacted B4> "if a <Redacted B4> is used on one day, it will be monitored under dynamic activity". This lack of viable air monitoring during active manufacturing phases fails to provide real-time assurance of aseptic conditions in a critical processing environment.
B. Your ISO 7 Buffer Room, ISO 8 Ante Room, and associated <Redacted B4>, which serve as essential <Redacted B4> for materials and personnel supporting ISO 5 aseptic operations, are sampled <Redacted B4> instead of <Redacted B4> during production. Your procedure P-204.7, "Quality Management Program for Environmenta and Personnel Sampling," explicitly states that "all support areas (ISO 7/8 buffer/ante/gowning room) in use will be monitored <Redacted B4>". ...
Observation 2
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A. Your disinfectant efficacy study is inadequate because it fails to demonstrate sporicidal activity. Your firm relies on <Redacted B4> with a <Redacted B4> contact time as its primaiy sporicidal agent for <Redacted B4> <Redacted B4> only <Redacted B4> and <Redacted B4> cleaning activities, as specified in SOP P-305.7 "Cleaning and Disinfection of ISO Classified Controlled Environments and Rooms". However, the validation for this agent, documented in the "Final Report for Disinfection Efficacy Test Study" (Protocol # PRO 22-002), is inadequate for this purpose. The protocol explicitly states that the challenge organisms Bacillus subtilis and Aspergillus brasiliensis were tested only in their vegetative state. The study did not include any testing against their respective highly resistant spores. Therefore, your fnm possesses no data to support the claim that your cleaning program is effective at killing bacterial or fungal spores, which is the prime reason for using a sporicidal agent. ...
Observation 3
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
A. Your firm's visual inspection program, as outlined in procedure P-614.5 "Visual Inspection of Ingredients and Compounded Sterile Preparations," fails to establish a scientifically sound and documented acceptance sampling plan. The required <Redacted B4> inspection by the Quality Services Unit after a I 00% visual inspection is arbitrary and lacks scientific justification. It is not explicitly tied to a statistically sound Acceptable Quality Limit (AQL) plan, such as ANSI/ASQ Zl.4, which is a standard for ensuring the quality of batches. Furthermore, the procedure mentions defect severities (Critical, Major, Minor) but does not provide specific AQL values (e.g., percentage of acceptable defects) for each category. ...
Observation 4
Specifically,
Your firm does not perform contemporaneous two-person verification of environmental monitoring plates. A single laboratory technician reads environmental plate samples and records the results of the plate counts on a worksheet. There is no assurance that the operator has entered the data accurately.
Observation 5
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
Your firm's Quality Unit lacks segregation of duties among personnel involved in quality control activities, thereby compromising the independence and integrity of quality oversight. Specifically, your Quality Unit, comprised of a single quality manager and one technician, assumes multifarious roles that include:
• Collection of environmental and personnel monitoring samples.
• Reading and interpretation of environmental and personnel monitoring sample results.
• Initiation and conduct of investigations into deviations, including out-of-specification (OOS) environmental monitoring results.
• Review of batch records for compliance.
• Final release of finished drug products for distribution.
For example, from 11/17/25 to 11/25/25, Quality & Testing Manager collected, incubated, and performed readings of lot related environmental monitoring samples for lot SUCC10020251114. On 11/25/25 the Q&T Manager segregated the lot and provided a partial release of the lot. ...
Observation 6
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
Your firm prematurely released a portion of drug product batch SUCC1002025 1114 for distribution prior to the initiation and completion of a thorough investigation into a detected microbial recovery, thereby failing to assure that the drug product meets its specifications for quality and purity before release. Specifically:
• Environmental monitoring samples collected during the processing of lot SUCC1002025 1114 detected a microbial recovery (single CFU on a pharmacist's <Redacted B4> glove cuff) on 11/24/25, as recorded during the final stage of incubation.
• On 11/25/25, your Quality & Testing Manager segregated the lot by loader and authorized a partial release of batch SUCC10020251114. The unaffected portion of the lot was deemed appropriate for release, and <Redacted B4> syringes from this portion were consequently released. ...
Observation 7
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Specifically,
Your firm's visual inspection procedures for products repackaged into intravenous (IV) bags are deficient. Your visual inspection procedures request to perform a 100% visual inspection of IV bags after bags have been labeled. For example, Batch Production Records F-671.ca for Oxytocin and F-671. <Redacted B4> for Fentanyl Ropivacaine Epidural, under the "Visual Inspection (light box)" section, state: "Observe each labelled bag in the light box for no less than <Redacted B4>. Check for product clarity and label for legibility." There is no assurance that the label, once applied to the IV bag, will not obstruct or impede the detection of particulates or other critical defects within the product.
Observation 8
All records of production associated with a batch of drug product were not maintained at least one (1) year after the expiration date.
Specifically,
Surveillance video is used by your firm for investigation of production discrepancies including but not limited to environmental and personnel monitoring excursions. Video recordings of gowning and production activities are described and referenced in written investigation reports and have been used to establish root cause. However, these video recordings are not maintained by your firm. Examples include but are not limited to the following:
• QRE 25-018 -"Video review showed <Redacted B4> failed to disinfect the vestibule door handle (a high-touch area) and did not perform SS&D after wiping materials down before loading",
• QRE 25-017 -"Video review showed <Redacted B4> failed to perform SS&D consistently and after retrieving supplies",
• QRE 25-016 -"Video review showed <Redacted B4> failed to change gloves after cleaning vestibules and did not fully SS&D cuffs", etc.
Observation 9
Written procedures are not established for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.
Specifically,
Your firm does not maintain written records for annual product reviews conducted for your aseptically produced drug products, including but not limited to the following information:
Trends, reports, or summaries of quality indicators, a summary of all media fills performed since last inspection, environmental monitoring trend data (microbial and particle counts), personnel monitoring trend data, evaluations of investigations and effectiveness of collective actions, change management, evaluation of unexpected results or trends, Out-of-Specification (OOS) results, product rejects, etc.
evaluation of unexpected results or trends, Out-of-Specification (OOS) results, product rejects, etc.
Inspection Nov 18, 2019 to Dec 10, 2019: 5 observations
- Firm on the cover
- BAYCARE INTEGRATED SERVICE CENTER, 7802 E Telecom Pkwy, Temple Terrace, FL 33637-0928
- FEI number
- 3013023419
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
1.) A quality related event (QRE) was not documented for ephedrine sulfate 25 mg/5 ml for injection in pre-filled syringes lot <Redacted B4> indicated for the treatment of clinically important hypotension occuring in the settmg of anesthesia prepared on 7/25/2019 with a reported pH of 4.17 on 7/31/2019 by a contract test lab used for release testing. There was no investigation documented into a possible root cause for a pH lower than previously obtained through stability studies on <Redacted B4> lots prepared from 6/17-19/2019 with pH measurements ranging from <Redacted B4> to <Redacted B4> and pH specifications with upper and lower limits were not established. The contract test laboratory reported a pH of 6.84 on 7/29/2019; 6.87 on 8/8/2019; 7.00 on 8/8/2019; 6.85 on 8/8/2019; and 6.80 on 8/22/2019. 189 of these pre-filled syringes were released for patient use on 8/26/2019 after a contract laboratory investigation determined that the final pH was 6.8. ...
Observation 2
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically, you have not established upper and lower pH specifications for the following sterile drug products prepared by your firm since 7/25/2019:
1. <Redacted B4> ephediine sulfate 25 mg/5 ml in pre-filled syringes
2.)
<Redacted B4> oxytocin 30 units in 500 ml NaCl 0.9% bags for injection
3.) <
Redacted B4> vancomycin 1250 mg in 500 ml NaCl 0.9% bags for injection
Observation 3
The responsibilities and procedures applicable to the quality control unit are not in writing.
Specifically, there is no written procedure for supplier and contract test lab qualifications. As an example, you have not assessed the compliance status of your contract test lab responsible for the control records and raw data to include release and stability testing for potency, endotoxin, sterility, and pH for all your sterile drug products.
Observation 4
Disinfectant contact time (also known as <Redacted B4> and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection .
Specifically, disinfection frequency and time are not specified and documented as evidence that they are applied consistently each time the sporicidal disinfectant is used.
1.) SOP P-305.4 Cleaning and Disinfection of ISO Classified Controlled Environments and Rooms did not include clear instrnctions or specifications on the use, frequency, and time sporicidal disinfectants are applied to the ISO 5 locations.
2.) SOP P-304.3 Cleaning and Disinfection of Materials and Supplies in the Controlled Sterile Compounding Environment did not include clear instructions on how the <Redacted B4> 'l will be monitored.
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, the air particle counter was not oriented in the direction of the horizontal first pass air when used to monitor particles in the <Redacted B4> laminar flow hood <Redacted B4> during the preparation of sterile drug products such as ephedrine 1000 mg q.s. with 200 ml in 0.9 % NaCl for injection lot <Redacted B4> and vancomycin 1250 mg in 500 ml 0.9 % NaCl for injection lot <Redacted B4>.
Linked 483s whose text is not shown
- Jun 2, 2023: FDA document 170667: its numbered observations could not be read reliably from the PDF text.
- Jun 2, 2023: FDA document 170879: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy). That is not a finding beyond this index’s search.
The BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.